{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-274508","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.394556+00:00","generated_at":"2026-06-22T19:56:33.939081+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Repligen Q3 revenue $200.7M (+13% YoY); raises FY revenue guidance to $795-$805M","bullets":["Revenue $200.7M, +13% reported, +19% constant currency, +16% organic; base business up 29% YoY.","GAAP EPS $0.71; adjusted EPS $0.77 (vs $0.78 Q3 2021); GAAP gross margin 56.9%.","FY 2022 revenue guidance raised to $795-$805M (from $790-$810M); base business growth raised to 33%-34%.","Adjusted EPS guidance narrowed to $3.15-$3.20 from $3.13-$3.20; operating income guidance lowered to $231-$235M.","Signed 15-year real-time process monitoring deal with DRS Daylight Solutions; extended Purolite affinity ligand agreement to 2032."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-274508","json":"https://secwatch.observer/filing/0001193125-22-274508.json","markdown":"https://secwatch.observer/filing/0001193125-22-274508.md","text":"https://secwatch.observer/filing/0001193125-22-274508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000119312522274508/0001193125-22-274508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000119312522274508/d394510d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T19:56:33.939081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"75fd7909e1bf4bc725e1cc3fe9dd4cab5919ad4d","claim":"REPLIGEN CORP reported the year 2022 results: revenue $795-$805 million.","evidence_excerpt":"YEAR 2022 GUIDANCE: • Total reported revenue is expected to be in the range of $795-$805 million, compared to our previous guidance of $790-$810 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/730272/000119312522274508/0001193125-22-274508-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year 2022"},{"label":"Revenue","value":"$795-$805 million"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"dc1f9da85e00b88923ec8e9e1e9c07463102b271","claim":"REPLIGEN CORP reported the third quarter ended September 30, 2022 results: revenue $200.7 million, net income $40.4 million, EPS $0.71 on a fully diluted basis.","evidence_excerpt":"Total revenue as reported for the third quarter of 2022 increased to $200.7 million compared to $178.2 million for the third quarter of 2021, a year-over-year gain of 13%, or 19% at constant currency, and organic growth of 16%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/730272/000119312522274508/0001193125-22-274508-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$200.7 million"},{"label":"Net income","value":"$40.4 million"},{"label":"EPS","value":"$0.71 on a fully diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}